{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:10:22Z","timestamp":1790244622083,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.leukres.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:18:01Z","timestamp":1523971081000},"page":"94-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The rising prevalence of chronic myeloid leukemia in France"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-6749","authenticated-orcid":false,"given":"Marc","family":"Delord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Foulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.04.008_bib0005","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2018.04.008_bib0010","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.04.008_bib0025","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.04.008_bib0030","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0035","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0040","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.04.008_bib0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0050","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0055","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0060","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/0284186X.2012.707784","article-title":"Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US","volume":"52","author":"Mandal","year":"2013","journal-title":"Acta Oncol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0065","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0075","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2018.04.008_bib0080","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0085","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"NCCN guidelines insights: chronic myeloid leukemia, version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.leukres.2018.04.008_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0095","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2018.04.008_bib0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1684\/bdc.2013.1876","article-title":"History of chronic myeloid leukemia: a paradigm in the treatment of cancer","volume":"101","author":"Gonon-Demoulian","year":"2014","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.leukres.2018.04.008_bib0105","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2018.04.008_bib0110","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","article-title":"Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU","volume":"94","author":"Conti","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 04 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.04.008_bib0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","article-title":"Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0125","doi-asserted-by":"crossref","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2018.04.008_bib0130","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1200\/jco.2008.26.15_suppl.7088","article-title":"Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib","volume":"26","author":"Corm","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0135","series-title":"The Materials and Methods of Demography Acad. New York. Shryock The Mater. Methods Demogr.","author":"Shryock","year":"1976"},{"key":"10.1016\/j.leukres.2018.04.008_bib0140","unstructured":"Institut National de la Statistique et des Etudes Economiques Le sc\u00e9nario central de projections de population 2007\u20132060 pour la France m\u00e9tropolitaine-Projections de population 2007\u20132060 pour la France m\u00e9tropolitaine | Insee. https:\/\/www.insee.fr\/fr\/statistiques\/2517722?sommaire=2020101#consulter-sommaire. Accessed 15 February 2018."},{"key":"10.1016\/j.leukres.2018.04.008_bib0145","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederrer","year":"1961","journal-title":"Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.leukres.2018.04.008_bib0150","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2011-01-330332","article-title":"Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990\u20132007: a population study","volume":"118","author":"Corm","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0155","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3109\/10428194.2014.974046","article-title":"Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980\u20132009","volume":"56","author":"Penot","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.04.008_bib0160","unstructured":"Institut national de la Statistique et des Etudes Economiques Estimation de la population au 1erjanvier 2018 | Insee. https:\/\/www.insee.fr\/fr\/statistiques\/1893198#documentation. Accessed 15 Febuary 2018."},{"key":"10.1016\/j.leukres.2018.04.008_bib0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.12695","article-title":"Chronic Myeloid Leukaemia in The Netherlands: a Population-Based Study on Incidence, Treatment and Survival in 3,585 Patients from 1989\u20132012","volume":"97","author":"Thielen","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0170","series-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2008"},{"key":"10.1016\/j.leukres.2018.04.008_bib0175","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3109\/10428194.2014.974046","article-title":"Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980\u20132009","volume":"56","author":"Penot","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.04.008_bib0180","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2018.04.008_bib0185","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3109\/10428194.2014.953141","article-title":"Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib","volume":"56","author":"Ohm","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.04.008_bib0190","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-014-2041-0","article-title":"Older patients with chronic myeloid leukemia (>65\u2009years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV","volume":"93","author":"Proetel","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0195","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"H\u00f6glund","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0200","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1056\/NEJM196605192742001","article-title":"Radiation-Related leukemia in Hiroshima and nagasaki, 1946\u20131964","volume":"274","author":"Bizzozero","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 2","key":"10.1016\/j.leukres.2018.04.008_bib0205","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0210","article-title":"Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology","volume":"8","author":"Zhao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.leukres.2018.04.008_bib0215","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia survival in the United States from 1975\u20132009","volume":"54","author":"Cheng","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.04.008_bib0220","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2018.04.008_bib0225","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.04.008_bib0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long term follow-up after imatinib cessation for patients indeep molecular response: the update results of the STIM1 study","volume":"122","author":"Rea","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.04.008_bib0235","unstructured":"Bureau UC 2014 National Population Projections Tables. https:\/\/www.census.gov\/data\/tables\/2014\/demo\/popproj\/2014-summary-tables.html. Accessed 29 January 2018."},{"key":"10.1016\/j.leukres.2018.04.008_bib0240","unstructured":"US Census Bureau DIS International Programs, International Data Base. https:\/\/www.census.gov\/data-tools\/demo\/idb\/informationGateway.php. Accessed 15 February 2018."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T22:51:53Z","timestamp":1571179913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618300948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":48,"alternative-id":["S0145212618300948"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.04.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rising prevalence of chronic myeloid leukemia in France","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}